Clinical Focus
Previous Articles Next Articles
Online:
Published:
Contact:
Abstract: Objective To observe the clinical value of serum claudin1 (Cla1), midkine (MK), and galectin1 (Gal1) levels in the diagnosis of Hashimoto thyroiditis (HT) with papillary thyroid cancer (PTC). Methods Totally 107 HT patients with PTC in our hospital from January 2018 to December 2019 were selected as HT with PTC group, meanwhile, 65 HT patients and 30 healthy people examined in our hospital during the same period were selected as the HT group and the healthy control group, respectively. The serum Cla1, MK and Gal1 levels were observed in each group. And the correlation among serum Cla1, MK and Gal1 levels in HT patients with PTC, HT stage, and TNM stage were also observed, as well as its diagnostic value for HT with PTC.Results The serum Cla1, MK and Gal1 levels in HT with PTC group were significantly higher than those in HT group and healthy control group (P<0.01). The serum Gal1 level in HT group was obviously higher than that in health control group (P<0.01). The levels of serum Cla1, MK and Gal1 in HT patients with PTC increased significantly with the increase of HT stage and TNM stage (P<0.01). The serum Cla1 level was positively correlated with MK and Gal1 levels in HT patients with PTC, and the serum MK was positively correlated with Gal1. The serum Cla1, MK and Gal1 levels had higher sensitivity and specificity in the diagnosis of HT with PTC. The sensitivity and specificity of the combined detection were 88.8% and 90.8%, respectively. And the AUC was 0.941, which was significantly higher than that measured by the detection of Cla1, MK and Gal1, respectively. Conclusion The Cla1, MK and Gal1 are involved in the development of HT with PTC, which havehigher diagnostic efficacy in predicting the occurrence of PTC in HT patients.
Key words: thyroid neoplasms, claudins, hemagglutinins
Tang Zhijin, Shen Hua, Yu Haiwen. Clinical value of serum Cla1, MK and Gal1 levels in diagnosis of Hashimoto thyroiditis with papillary thyroid cancer[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2020.03.013.
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2020.03.013
https://huicui.hebmu.edu.cn/EN/Y2020/V35/I3/255